IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell

IRF1通过上调肿瘤细胞中的PD-L1抑制抗肿瘤免疫

阅读:3
作者:Lulu Shao ,Weizhou Hou ,Nicole E Scharping ,Frank P Vendetti ,Rashmi Srivastava ,Chandra Nath Roy ,Ashley V Menk ,Yiyang Wang ,Joe-Marc Chauvin ,Pooja Karukonda ,Stephen H Thorne ,Veit Hornung ,Hassane M Zarour ,Christopher J Bakkenist ,Greg M Delgoffe ,Saumendra N Sarkar

Abstract

Multiple studies have associated the transcription factor IRF1 with tumor-suppressive activities. Here, we report an opposite tumor cell-intrinsic function of IRF1 in promoting tumor growth. IRF1-deficient tumor cells showed reduced tumor growth in MC38 and CT26 colon carcinoma and B16 melanoma mouse models. This reduction in tumor growth was dependent on host CD8+ T cells. Detailed profiling of tumor-infiltrating leukocytes did not show changes in the various T-cell and myeloid cell populations. However, CD8+ T cells that had infiltrated IRF1-deficieint tumors in vivo exhibited enhanced cytotoxicity. IRF1-deficient tumor cells lost the ability to upregulate PD-L1 expression in vitro and in vivo and were more susceptible to T-cell-mediated killing. Induced expression of PD-L1 in IRF1-deficient tumor cells restored tumor growth. These results indicate differential activity of IRF1 in tumor escape.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。